Lisata Therapeutics reported a decrease in operating expenses to $4.4 million, net loss reduced to $4.2 million, and cash reserves at $19 million, extending runway into 2027. Positive preliminary data from ASCEND trial and ASCEND Safety showed no increased adverse events in treated groups. Strategic alliances with Catalent and GATC Health, patent extension, and ongoing clinical trials progress were highlighted. Management seeks additional funding for Phase III ASCEND trial, focusing on capital acquisition and strategic partnerships. Financial results, trial updates, and strategic initiatives were discussed in detail during the conference call.

Read more at Nasdaq.: Lisata (LSTA) Q3 2025 Earnings Call Transcript